Alk Inhibitors in the Adjuvant Setting - Any Thoughts?

So I want to get into another sort of generic issue, which is the issue of the adjuvant therapy in patient with target lung mutation. So now right now, that's restricted to Osamurtinib and EGFR. And Ross, this is a great editorial you did about that going into all the complexities of the Adora situation. But it certainly would not be a surprise if both of these strategies end up maybe not having a survival benefit, but not necessarily being ruled out even if they don't have a survival benefit.